RI-ADE ADME 101: Non-clinical pharmacokinetics studies using radio-labeled compounds
Presenter: Satoshi Ito, Drug Development Solutions Center ADME Group Manager, Sekisui Medical
Radio-labeled compounds can be used to provide important information during the drug development process. Whole-body exposure, mass balance (excretion route and excretion rate) and metabolite profiling/identification are the most common studies conducted using radiolabeled compounds. In this webinar, we will be discussing the basics of ADE studies using radiolabeled compounds and go over a few of the common studies that are conducted at the Drug Development Solutions Center in Japan.
About the Presenter:
Mr. Satoshi Ito serves as a Manager in the ADME group at the Drug Development Solutions Center for Sekisui Medical, Co. Ltd (Japan). He received his MS degree from the School of Pharmaceutical Sciences at the Tokyo University of Science and has been with Sekisui Medical since 2005. He first operated as a research scientist, then moved to the Business Planning and Development team as Business Development Manager, responsible for the global marketing of ADME studies. In his current role, he is responsible for all in vivo ADME contract studies for both domestic and international clients.